Drug Price Transparency Bills May Be Empty Calories
Price justification legislation is advancing in both chambers of Congress. But CBO scores them as no savings.
You may also be interested in...
Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.
Legislation pending in US House Energy and Commerce Committee would exempt drugs treating diseases with less than 200,000 patients from needing to justify price increases.
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.